Pharmacology and clinical efficacy of cholinesterase inhibitors

American Journal of Health-System Pharmacy

Volumn 55, Issue 21 SUPPL., 1998, Pages

  Jann, Michael W ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Clinical studies; Donepezil; Drug comparisons; Drugs, clinical effectiveness; Parasympathomimetic agents; Pharmacokinetics; Physostigmine; Rivastigmine; Tacrine; Toxicity; Trichlorf on

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; METRIFONATE; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BRADYCARDIA; COGNITION; CONFERENCE PAPER; DAILY LIFE ACTIVITY; DRUG EFFICACY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; LEG CRAMP; LIVER TOXICITY; PRIORITY JOURNAL; PROTEIN PROCESSING;

EID: 0032213644     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.suppl_2.s22     Document Type: Conference Paper

References (22)

1. Parnetti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease: the way forward. Drugs 1997; 53:752-68.
2. Sramek JJ, Anand R, Wardle TS et al. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci. 1996; 58:1201-7.
3. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging. 1994; 4:510-40.
4. Franks AS, Rawls WN. Alzheimer's disease: clinical features and pharmacologic management. Am J Manag Care. 1998; 4:595-604.
5. Aricept package insert. New York: Roerig, Division of Pfizer, Inc.; 1996.
6. Ohnishi A, Mihara M, Kamakura H et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol. 1993; 33:1086-91.
7. Hinz VC, Grewig S, Schmidt BH. Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res. 1996; 21:331-7.
8. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141:1356-64.
9. Mohs RC, Cohen L. Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull. 1988; 24:627-8.
10. Knopman DS, Knapp MJ, Gracon SI et al. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology. 1994; 44:2315-21.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-98.
12. Farlow M, Gracon SI, Hershey LA et al. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA. 1992; 268:2523-9.
13. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia. 1996; 7:293-303.
14. Cutler NR, Jhee SS, Cyrus P et al. Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study. Life Sci. 1998; 62:1433-41.
15. Rogers SL, Farlow MR, Doody RS et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998; 50:136-45.
16. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract. 1996; 8:109-16.
17. Cummings JL, Cyrus PA, Bieber F et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology. 1998; 50:1214-21.
18. Farlow MR, Cyrus PA, Gulanski B. Metrifonate improves the cognitive deficits of Alzheimer's disease patients in a dose-related manner. Paper presented at American Geriatrics Society/American Federation for Aging Research 1998 Annual Scientific Meeting. Seattle; 1998 May 6-9.
19. Cummings JL, Cyrus PA, Gulanski B. Metrifonate efficacy in the treatment of psychiatric and behavioral disturbances of Alzheimer's disease patients. Paper presented at American Geriatrics Society/American Federation for Aging Research 1998 Annual Scientific Meeting. Seattle; 1998 May 6-9.
20. Gauthier S, Gélinas I, Cyrus PA et al. Metrifonate enhances the ability of Alzheimer's disease patients to perform instrumental and basic activities of daily living. Paper presented at American Geriatrics Society/American Federation for Aging Research 1998 Annual Scientific Meeting. Seattle; 1998 May 6-9.
21. Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol. 1996; 9:1-6.
22. Cummings JL, Cyrus PA, Ruzicka BB et al. The efficacy of metrifonate in improving the behavioral disturbances of Alzheimer's disease patients. Paper presented at American Academy of Neurology 1998 Annual Meeting. Minneapolis; 1998 Apr 25-May 3.